Research Insight

Gilead’s Harvoni receives FDA approval for hepatitis C genotype 1 infection

Gilead Sciences has received approval from US Food and Drug Administration for Harvoni (ledipasvir 90mg/sofosbuvir 400mg), a once-daily single tablet regimen to treat chronic hepatitis C genotype 1 infection in adults. Obtained approval...

EMD Serono, ICR and Wellcome Trust partner develop anti-cancer drugs

Merck subsidiary EMD Serono, The Institute of Cancer Research (ICR) and the Wellcome Trust have entered into a co-development and licence agreement for new drug candidates to treat different forms of cancer. The ...

Novartis and BMS enter clinical collaboration to assess lung cancer treatments

Swiss drug maker Novartis has partnered with US-based Bristol-Myers Squibb (BMS) to assess the safety, tolerability and preliminary efficacy of its three molecularly targeted compounds in combination with BMS's Opdivo (nivolumab). The investigational...

UK’s Medical Research Council grants fund for three new research programmes

The UK Medical Research Council (MRC) has granted a fund of £6m for three new research programmes, as part of a £60m investment. The investment will be used to study biological mechanisms of Parkinson's disease and reduced...

Afatinib drug could inhibit growth of womb cancer, say Yale scientists

Research conducted by scientists from the Yale School of Medicine gynaecologic oncology division has demonstrated that the drug afatinib could inhibit the growth of womb cancer and shrink tumours. The research published...

PANEL: FLU SPRAY BETTER THAN SHOTS FOR YOUNG KIDS

When it comes to flu vaccines, a federal panel says a squirt in the nose is better than a shot in the arm for young children. The advisory panel voted Wednesday to advise doctors that FluMist...

Reducing readmissions: Top strategy for improving quality, lowering costs

Dr. Fortuna says payers should consider expand their perspectives on improving the healthcare system by adopting the use of the tools, methodologies and quality improvement professionals (engineers) that other industries have with great success as recommended in the May...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read